Seres Therapeutics Stock Performance
| MCRB Stock | USD 0.77 0.03 4.05% |
Seres Therapeutics has a performance score of 1 on a scale of 0 to 100. The entity has a beta of 1.49, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Seres Therapeutics will likely underperform. Seres Therapeutics right now has a risk of 5.95%. Please validate Seres Therapeutics expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Seres Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Seres Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Seres Therapeutics is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
1 | Disposition of 2983 shares by Young Teresa L. of Seres Therapeutics at 0.6901 subject to Rule 16b-3 | 10/28/2024 |
2 | Acquisition by Von Moltke Lisa of 2969 shares of Seres Therapeutics subject to Rule 16b-3 | 11/01/2024 |
3 | Acquisition by Von Moltke Lisa of 287905 shares of Seres Therapeutics at 1.1 subject to Rule 16b-3 | 11/11/2024 |
4 | Seres Therapeutics GAAP EPS of -0.33 misses by 0.25 | 11/13/2024 |
5 | Seres Therapeutics Inc Q3 2024 Earnings Call Highlights Strategic Moves and Clinical ... | 11/14/2024 |
6 | Little Excitement Around Seres Therapeutics, Inc.s Revenues As Shares Take 30 percent Pounding | 11/15/2024 |
7 | Disposition of 927 shares by Matthew Henn of Seres Therapeutics at 0.5407 subject to Rule 16b-3 | 11/18/2024 |
8 | Seres Therapeutics chief legal officer sells shares worth 474 | 11/19/2024 |
9 | Seres Therapeutics to Participate in Piper Sandler Healthcare Conference | 11/22/2024 |
10 | Global Antibiotics Market is Expected to Reach USD 59 Billion by 2030 DelveInsight | 12/05/2024 |
11 | FDA Grants Breakthrough Therapy Designation to Seres Therapeutics SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic ... | 12/09/2024 |
12 | Microbiome-Based Therapeutics Thematic Intelligence Research Report 2024 Focus on 7MM - US, France, Germany, Italy, Spain, the UK, and Japan | 01/10/2025 |
13 | Microbiomes Market to Grow by USD 1.13 Billion , Driven by Rising Disease Prevalence AI Impact on Market Trends - Technavio | 01/17/2025 |
| Begin Period Cash Flow | 171.2 M |
Seres |
Seres Therapeutics Relative Risk vs. Return Landscape
If you would invest 81.00 in Seres Therapeutics on October 20, 2024 and sell it today you would lose (4.00) from holding Seres Therapeutics or give up 4.94% of portfolio value over 90 days. Seres Therapeutics is currently generating 0.0857% in daily expected returns and assumes 5.9458% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Seres, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Seres Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Seres Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Seres Therapeutics, and traders can use it to determine the average amount a Seres Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0144
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | MCRB | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.95 actual daily | 52 52% of assets are less volatile |
Expected Return
| 0.09 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average Seres Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Seres Therapeutics by adding it to a well-diversified portfolio.
Seres Therapeutics Fundamentals Growth
Seres Stock prices reflect investors' perceptions of the future prospects and financial health of Seres Therapeutics, and Seres Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Seres Stock performance.
| Return On Equity | -15.56 | ||||
| Return On Asset | -0.097 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.34) % | ||||
| Current Valuation | 157.81 M | ||||
| Shares Outstanding | 170.74 M | ||||
| Price To Earning | (4.04) X | ||||
| Price To Book | 5.48 X | ||||
| Price To Sales | 1.04 X | ||||
| Revenue | 126.33 M | ||||
| Gross Profit | 23.26 M | ||||
| EBITDA | (94.31 M) | ||||
| Net Income | (113.72 M) | ||||
| Cash And Equivalents | 195.8 M | ||||
| Cash Per Share | 1.58 X | ||||
| Total Debt | 213.94 M | ||||
| Debt To Equity | 3.35 % | ||||
| Current Ratio | 2.35 X | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (117.35 M) | ||||
| Earnings Per Share | (0.42) X | ||||
| Market Capitalization | 131.02 M | ||||
| Total Asset | 358.6 M | ||||
| Retained Earnings | (978.24 M) | ||||
| Working Capital | 76.75 M | ||||
| Current Asset | 207.61 M | ||||
| Current Liabilities | 10.92 M | ||||
About Seres Therapeutics Performance
By analyzing Seres Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Seres Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Seres Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Seres Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 13.8 K | 14.5 K | |
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | 2.92 | 3.06 |
Things to note about Seres Therapeutics performance evaluation
Checking the ongoing alerts about Seres Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Seres Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Seres Therapeutics had very high historical volatility over the last 90 days | |
| Seres Therapeutics has some characteristics of a very speculative penny stock | |
| Seres Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 126.33 M. Net Loss for the year was (113.72 M) with profit before overhead, payroll, taxes, and interest of 23.26 M. | |
| Seres Therapeutics currently holds about 195.8 M in cash with (117.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.58, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Seres Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 13.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Microbiomes Market to Grow by USD 1.13 Billion , Driven by Rising Disease Prevalence AI Impact on Market Trends - Technavio |
- Analyzing Seres Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Seres Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Seres Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Seres Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Seres Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Seres Therapeutics' stock. These opinions can provide insight into Seres Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Seres Stock analysis
When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |